adminの記事一覧

Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy.

Nephron Clin Pract. 112(3): c148-156, 2009.PubMed

Tubular and glomerular injury in diabetes and the impact of ACE inhibition.

Diabetes Care. 32(9): 1684-1688, 2009.PubMed

Monitoring of urinary L-type fatty acid-binding protein predicts histological severity of acute kidney injury.

Am J Pathol. 174(4): 1154-1159, 2009.PubMed

Urinary liver-type fatty acid-binding protein in septic shock: effect of polymyxin B-immobilized fiber hemoperfusion.

Shock. 31(5): 454-459, 2009.PubMed

Effect of red wine on urinary protein, 8-hydroxydeoxyguanosine, and liver-type fatty acid-binding protein excretion in patients with diabetic nephropathy.

Metabolism. 58(8): 1185-1190, 2009.PubMed

Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice.

Nephrol Dial Transplant. 24(3): 788-800, 2009.PubMed

Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury.

Nephron Exp Nephrol. 108(1): e19-26, 2008.PubMed

Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery.

Kidney Int. 73(4): 465-472, 2008.PubMed

Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury.

Kidney Int. 73(12): 1374-1384, 2008.PubMed

Renoprotective effect of telmisartan in patients with chronic kidney disease.

Clin Exp Hypertens. 30(7): 662-672, 2008.PubMed